With the inception of direct oral anticoagulants and potent P2Y12 inhibitors, clinical decisions on triple therapy remain controversial in the ability to optimize the balance between prevention of stroke and ST without unduly increasing bleeding risk. Here, P2RY12 is linked to Stroke.